Burkholderia cepacia complex in cystic fibrosis: critical gaps in diagnosis and therapy

References

• Rhodes KA, Schweizer HP. Antibiotic resistance in burkholderia species. Drug Resist Updat. 2016;28:1–10. doi: 10.1016/j.drup.2016.07.003.
   PubMed Web of Science ®Google Scholar
• Parfitt KM, Green AE, Connor TR, et al. Identification of two distinct phylogenomic lineages and model strains for the understudied cystic fibrosis lung pathogen Burkholderia multivorans. Microbiology (Reading). 2023;169(8):001366. doi: 10.1099/mic.0.001366.
   PubMedGoogle Scholar
• Fainardi V, Neglia C, Muscarà M, et al. Multidrug-resistant bacteria in children and adolescents with cystic fibrosis. Children (Basel). 2022;9(9):1330. doi: 10.3390/children9091330.
   PubMed Web of Science ®Google Scholar
• Ferreira MR, Gomes SC, Moreira LM. Mucoid switch in Burkholderia cepacia complex bacteria: triggers, molecular mechanisms and implications in pathogenesis. Adv Appl Microbiol. 2019;107:113–140. In: academic Press Inc doi: 10.1016/bs.aambs.2019.03.001.
   PubMed Web of Science ®Google Scholar
• Lauman P, Dennis JJ. Advances in phage therapy: targeting the Burkholderia cepacia complex. Viruses. 2021;13(7):1331. doi: 10.3390/v13071331.
   PubMed Web of Science ®Google Scholar
• Seelman SL, Bazaco MC, Wellman A, et al. Burkholderia cepacia complex outbreak linked to a no-rinse cleansing foam product, United States - 2017-2018. Epidemiol Infect. 2022;150:e154. doi: 10.1017/S0950268822000668.s
   PubMed Web of Science ®Google Scholar
• Sfeir MM. Burkholderia cepacia complex infections: more complex than the bacterium name suggest. J Infect. 2018;77(3):166–170. doi: 10.1016/j.jinf.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Maki Al-Nasrawy L, Abdali SA, Mohammed Jawad S. Molecular research comparing the probabilities of Burkholderia cepacia bacterium diagnosis procedures. Arch Razi Inst. 2022;77(2):717–725. doi: 10.22092/ARI.2022.357464.2041.
   PubMedGoogle Scholar
• McAvoy AC, Jaiyesimi O, Threatt PH, et al. Differences in cystic fibrosis-associated burkholderia spp. bacteria metabolomes after exposure to the antibiotic trimethoprim. ACS Infect Dis. 2020;6(5):1154–1168. doi: 10.1021/acsinfecdis.9b00513.
   PubMed Web of Science ®Google Scholar
• Häfliger E, Atkinson A, Marschall J. Systematic review of healthcare-associated Burkholderia cepacia complex outbreaks: presentation, causes and outbreak control. Infect Prev Pract. 2020;2(3):100082. doi: 10.1016/j.infpip.2020.100082.
   PubMedGoogle Scholar
• Angrup A, Kanaujia R, Biswal M, et al. Systematic review of ultrasound gel associated Burkholderia cepacia complex outbreaks: clinical presentation, sources and control of outbreak. Am J Infect Control. 2022;50(11):1253–1257. doi: 10.1016/j.ajic.2022.02.005.
   PubMed Web of Science ®Google Scholar
• Silmon T, Chapman D. What’s in your bottle? Investigating a pseudo-outbreak of Burkholderia cepacia. Am J Infect Control. 2019;47(6):S8–S9. doi: 10.1016/j.ajic.2019.04.152.
   Google Scholar
• Becker SL, Berger FK, Feldner SK, et al. Outbreak of Burkholderia cepacia complex infections associated with contaminated octenidine mouthwash solution, Germany, august to september 2018. Euro Surveill. 2018;23(42):1800540. doi: 10.2807/1560-7917.ES.2018.23.42.1800540.
   Google Scholar
• Bender JK, Haller S, Pfeifer Y, et al. Combined clinical, epidemiological, and genome-based analysis identified a nationwide outbreak of Burkholderia cepacia complex infections caused by contaminated mouthwash solutions. Open Forum Infect Dis. 2022;9(5):ofac114. doi: 10.1093/ofid/ofac114.
   PubMed Web of Science ®Google Scholar
• Tüfekci S, Şafak B, Nalbantoğlu B, et al. Burkholderia cepacia complex bacteremia outbreaks among non-cystic fibrosis patients in the pediatric unit of a university hospital. Turk J Pediatr. 2021;63(2):218–222. doi: 10.24953/turkjped.2021.02.005.
   PubMed Web of Science ®Google Scholar
• Bilgin H, Altınkanat Gelmez G, Bayrakdar F, et al. An outbreak investigation of Burkholderia cepacia infections related with contaminated chlorhexidine mouthwash solution in a tertiary care center in Turkey. Antimicrob Resist Infect Control. 2021;10(1):143. doi: 10.1186/s13756-021-01004-8.
   PubMed Web of Science ®Google Scholar
• Wong SCY, Wong S-C, Chen JHK, et al. Polyclonal Burkholderia cepacia complex outbreak in peritoneal dialysis patients caused by contaminated aqueous chlorhexidine. Emerg Infect Dis. 2020;26(9):1987–1997. doi: 10.3201/eid2609.191746.
   PubMed Web of Science ®Google Scholar
• Singh S, Sharma A, Nag V. Bacterial pathogens from lower respiratory tract infections: a study from Western Rajasthan. J Family Med Prim Care. 2020;9(3):1407–1412. doi: 10.4103/jfmpc.jfmpc_994_19.
   PubMedGoogle Scholar
• Shi H, Chen X, Chen L, et al. Burkholderia cepacia infection in children without cystic fibrosis: a clinical analysis of 50 cases. Front Pediatr. 2023;11:1115877. doi: 10.3389/fped.2023.1115877.
   PubMedGoogle Scholar
• Nye C, Duckers J, Dhillon R. Cefiderocol to manage chronic, multi-drug-resistant Burkholderia cepacia complex infection in a patient with cystic fibrosis: a case report. Access Microbiol. 2022;4(10):acmi000413. doi: 10.1099/acmi.0.000413.
   PubMedGoogle Scholar
• Daccò V, Alicandro G, Consales A, et al. Cepacia syndrome in cystic fibrosis: a systematic review of the literature and possible new perspectives in treatment. Pediatr Pulmonol. 2023;58(5):1337–1343. doi: 10.1002/ppul.26359.
   PubMed Web of Science ®Google Scholar
• Somayaji R, Yau YCW, Tullis E, et al. Clinical outcomes associated with Burkholderia cepacia complex infection in patients with cystic fibrosis. Ann Am Thorac Soc. 2020;17(12):1542–1548. doi: 10.1513/AnnalsATS.202003-204OC.
   PubMed Web of Science ®Google Scholar
• Bierlaagh MC, Muilwijk D, Beekman JM, et al. A new era for people with cystic fibrosis. Eur J Pediatr. 2021;180(9):2731–2739. doi: 10.1007/s00431-021-04168-y.
   PubMed Web of Science ®Google Scholar
• Klimko A, Brandt A, Brustan M-I, et al. A case report of cystic fibrosis complicated by Burkholderia cepacia and cutaneous vasculitis. Cureus. May 2020;12(5):e8158. doi: 10.7759/cureus.8158.
   PubMed Web of Science ®Google Scholar
• Masood A, Jacob M, Gu X, et al. Distinctive metabolic profiles between cystic fibrosis mutational subclasses and lung function. Metabolomics. 2021;17(1):4. doi: 10.1007/s11306-020-01760-5.
   PubMed Web of Science ®Google Scholar
• Dickinson KM, Collaco JM. Cystic fibrosis. Pediatr Rev. 2021;42(2):55–67. doi: 10.1542/pir.2019-0212.
   PubMed Web of Science ®Google Scholar
• López-Valdez JA, Aguilar-Alonso LA, Gándara-Quezada V, et al. Cystic fibrosis: current concepts. Bol Med Hosp Infant Mex. 2021;78(6):584–596. doi: 10.24875/BMHIM.20000372.
   PubMed Web of Science ®Google Scholar
• Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022;21(3):456–462. doi: 10.1016/j.jcf.2022.01.009.
   PubMed Web of Science ®Google Scholar
• Rosales-Reyes R, Rodríguez-Alvarado M, Lezana-Fernández JL, et al. Pseudomonas aeruginosa isolates from a cohort of mexican children with cystic fibrosis show adaptation to a chronic phenotype. Pediatr Infect Dis J. 2020;39(10):899–906. doi: 10.1097/INF.0000000000002714.
   PubMed Web of Science ®Google Scholar
• Lund-Palau H, Turnbull AR, Bush A, et al. Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches. Expert Rev Respir Med. 2016;10(6):685–697. doi: 10.1080/17476348.2016.1177460.
   PubMed Web of Science ®Google Scholar
• Shteinberg M, Haq IJ, Polineni D, et al. Cystic fibrosis. Lancet. 2021;397(10290):2195–2211. doi: 10.1016/S0140-6736(20)32542-3.
   PubMed Web of Science ®Google Scholar
• Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 2010;5(11):1663–1674. doi: 10.2217/fmb.10.125.
   PubMed Web of Science ®Google Scholar
• Sousa A, Pereira M. Pseudomonas aeruginosa diversification during infection development in cystic fibrosis lungs—a review. Pathogens. 2014;3(3):680–703. doi: 10.3390/pathogens3030680.
   PubMedGoogle Scholar
• Rosales-Reyes R, Vargas-Roldán SY, Lezana-Fernández JL, et al. Pseudomonas aeruginosa: genetic adaptation, a strategy for its persistence in cystic fibrosis. Arch Med Res. 2021;52(4):357–361. doi: 10.1016/j.arcmed.2020.12.004.
   PubMed Web of Science ®Google Scholar
• Blanchard AC, Waters VJ. Microbiology of cystic fibrosis airway disease. Semin Respir Crit Care Med. 2019;40(6):727–736. doi: 10.1055/s-0039-1698464.
   PubMed Web of Science ®Google Scholar
• Behroozian S, Zlosnik JEA, Xu W, et al. Antibacterial activity of a natural clay mineral against Burkholderia cepacia complex and other bacterial pathogens isolated from people with cystic fibrosis. Microorganisms. 2023;11(1):150. doi: 10.3390/microorganisms11010150.
   PubMed Web of Science ®Google Scholar
• Van Dalem A, Herpol M, Echahidi F, et al. In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam. Antimicrob Agents Chemother. 2018;62(9):e00590-18. doi: 10.1128/AAC.00590-18.
   PubMed Web of Science ®Google Scholar
• Marrs ECL, Perry A, Perry JD. Evaluation of three culture media for isolation of Burkholderia cepacia complex from respiratory samples of patients with cystic fibrosis. Microorganisms. 2021;9(12):2604. doi: 10.3390/microorganisms9122604.
   PubMed Web of Science ®Google Scholar
• Naqvi S, Varadhan H, Givney R. Is prolonged incubation required for optimal recovery of Burkholderia cepacia complex in sputum from cystic fibrosis patients? Data versus dogma. Pathology. 2020;52(3):366–369. doi: 10.1016/j.pathol.2019.11.011.
   PubMed Web of Science ®Google Scholar
• Lupo A, Isis E, Tinguely R, et al. Clonality and antimicrobial susceptibility of Burkholderia cepacia complex isolates collected from cystic fibrosis patients during 1998-2013 in Bern, Switzerland. New Microbiol. 2015;38(2):281–288. http://www.ncbi.nlm.nih.gov/pubmed/25938755.
   PubMed Web of Science ®Google Scholar
• Akkerman-Nijland AM, Rottier BL, Holstein J, et al. Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole. ERJ Open Res. 2023;9(3):00055–02023. doi: 10.1183/23120541.00055-2023.
   PubMedGoogle Scholar
• Regan KH, Bhatt J. Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. 2019;4(4):CD009876. doi: 10.1002/14651858.CD009876.pub4.
   PubMedGoogle Scholar
• Kordes A, Preusse M, Willger SD, et al. Genetically diverse Pseudomonas aeruginosa populations display similar transcriptomic profiles in a cystic fibrosis explanted lung. Nat Commun. 2019;10(1):3397. doi: 10.1038/s41467-019-11414-3.
   PubMedGoogle Scholar
• Óscar Fielbaum C. Avances en fibrosis quística. Rev Médica Clínica Las Condes. 2011;22(2):150–159. doi: 10.1016/S0716-8640(11)70407-2.
   Google Scholar
• Sousa SA, Seixas AMM, Marques JMM, et al. Immunization and immunotherapy approaches against Pseudomonas aeruginosa and Burkholderia cepacia complex infections. Vaccines (Basel). 2021;9(6):670. doi: 10.3390/vaccines9060670.
   PubMed Web of Science ®Google Scholar
• Jorgensen JH, Jorgensen JH, Carroll Funke, et al. Manual of clinical microbiology. (KCG  eds.). Washington, DC, USA: ASM Press; 2015. doi: 10.1128/9781555817381.
   Google Scholar
• Pachori P, Gothalwal R, Gandhi P. Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review. Genes Dis. 2019;6(2):109–119. doi: 10.1016/j.gendis.2019.04.001.
   PubMed Web of Science ®Google Scholar
• Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. doi: 10.1016/S0140-6736(21)02724-0.
   PubMed Web of Science ®Google Scholar
• Landes NJ, Livesay HN, Schaeffer F, et al. Burkholderia cepacia: a complex problem for more than cystic fibrosis patients. Clin Microbiol Newsl. 2016;38(18):147–150. doi: 10.1016/j.clinmicnews.2016.08.003.
   Google Scholar
• Devanga Ragupathi NK, Veeraraghavan B. Accurate identification and epidemiological characterization of Burkholderia cepacia complex: an update. Ann Clin Microbiol Antimicrob. 2019;18(1):7. doi: 10.1186/s12941-019-0306-0.
   PubMedGoogle Scholar
• Fehlberg LCC, Andrade LHS, Assis DM, et al. Performance of MALDI-ToF MS for species identification of Burkholderia cepacia complex clinical isolates. Diagn Microbiol Infect Dis. 2013;77(2):126–128. doi: 10.1016/j.diagmicrobio.2013.06.011.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gao W, Yin Y, et al. Discrimination of Burkholderia gladioli pv.alliicola and B. cepacia complex using the gyrB gene of B. gladioli pv. alliicola. Exp Ther Med. 17December 2018;17(3):1870–1876. doi: 10.3892/etm.2018.7137.
   PubMed Web of Science ®Google Scholar
• Tabacchioni S, Ferri L, Manno G, et al. Use of the gyrB gene to discriminate among species of the Burkholderia cepacia complex. FEMS Microbiol Lett. 2008;281(2):175–182. doi: 10.1111/j.1574-6968.2008.01105.x.
   PubMed Web of Science ®Google Scholar
• Gaibani P, Giani T, Bovo F, et al. Resistance to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam in Gram-Negative MDR bacilli: molecular mechanisms and susceptibility testing. Antibiotics (Basel). 2022;11(5):628. doi: 10.3390/antibiotics11050628.
   PubMed Web of Science ®Google Scholar
• Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. Front Public Heal. 2014;2:145. doi: 10.3389/fpubh.2014.00145.
   PubMedGoogle Scholar
• Gashaw M, Berhane M, Bekele S, et al. Emergence of high drug resistant bacterial isolates from patients with health care associated infections at jimma university medical center: a cross sectional study. Antimicrob Resist Infect Control. 2018;7(1):138. doi: 10.1186/s13756-018-0431-0.
   PubMed Web of Science ®Google Scholar
• Irudal S, Scoffone VC, Trespidi G, et al. Identification by reverse vaccinology of three virulence factors in Burkholderia cenocepacia that may represent ideal vaccine antigens. Vaccines (Basel). 2023;11(6):1039. doi: 10.3390/vaccines11061039.
   PubMed Web of Science ®Google Scholar
• Frost F, Shaw M, Nazareth D. Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. 2019;6(6):CD013079. doi: 10.1002/14651858.CD013079.pub2.
   PubMedGoogle Scholar
• Frost F, Shaw M, Nazareth D. Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database Syst Rev. 2021;12(12):CD013079. doi: 10.1002/14651858.CD013079.pub3.
   PubMedGoogle Scholar
• Haidar G, Chan BK, Cho S-T, et al. Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans. Transpl Infect Dis. 2023;25(2):e14041. doi: 10.1111/tid.14041.
   PubMed Web of Science ®Google Scholar
• Lloyd EC, Cogen JD, Maples H, et al. Antimicrobial stewardship in cystic fibrosis. J Pediatric Infect Dis Soc. 2022;11(Supplement_2):S53–S61. doi: 10.1093/jpids/piac071.
   PubMedGoogle Scholar
• Babich T, Naucler P, Valik JK, et al. Duration of treatment for Pseudomonas aeruginosa bacteremia: a retrospective study. Infect Dis Ther. 2022;11(4):1505–1519. doi: 10.1007/s40121-022-00657-1.
   PubMed Web of Science ®Google Scholar
• Middleton PG, Kidd TJ, Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex. Eur Respir J. 2005;26(2):305–308. doi: 10.1183/09031936.05.00119504.
   PubMed Web of Science ®Google Scholar
• Cui X, Lü Y, Yue C. Development and research progress of anti-drug resistant bacteria drugs. Infect Drug Resist. 2021;volume14:5575–5593. doi: 10.2147/IDR.S338987.
   PubMed Web of Science ®Google Scholar
• Lewis K. The science of antibiotic discovery. Cell. 2020;181(1):29–45. doi: 10.1016/j.cell.2020.02.056.
   PubMed Web of Science ®Google Scholar